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Abstract 
 
Tumour cells of classical Hodgkin’s lymphoma (cHL) comprise only a fraction (1% or 
less) of the total cellular infiltrate. The low tumour cell numbers pose a great difficulty 
in the investigation of underlying genetic events in cHL development. This hurdle can 
be overcome by exome sequencing of a small number (~50) of isolated HL cells. 
This study was aimed at establishing ‘whole genome amplification (WGA) of the HL 
cell lines and patients’ samples, which can be potentially used to for the exome 
sequencing. This study used 6 HL cell lines (HDLM-2, KM-H2, L-428, L540, L-591, 
and L-1236) and 4 HL patients’ samples (1.5, 6.4, 7.28, and 7.8) to generate PCR 
products for exons 2 to 9 of the TNFAIP3 gene. We also aimed to demonstrate 
whether microdissection and whole genome amplification methods will introduce any 
changes to the sequences, by analysing the mutation spectra for the whole genome 
‘amplified’, and ‘unamplified’ (KM-H2 and L-591) cell lines. We obtained good quality 
WGA product for all the microdissected cell line samples and patient samples. 
However, only patient sample 6.4 amplified all of these exons except the exon 6 and 
7.1 in the following PCR experiments. The quality of the sequences obtained for the 
amplified cell line samples (76.5%) was as good as the quality for the unamplified 
cell lines (79.7%). We observed same nucleotide changes in the cell lines KM-H2 
(deletion of intron 2– exon 6 region), and L-1236 (G491A) as reported in a previous 
study (16).  
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1) Introduction 
 
Hodgkin’s lymphoma (HL) is one of the most prevalent types of malignant 
lymphomas in the western countries, with an incidence rate of 3 in 100,000 persons 
each year.  In the United Kingdom (UK), 1,852 people diagnosed with HL, and 319 
HL related deaths were registered between the year 2009 and 2010.  Although HL 
accounts for less than 1% of all cancers in the UK (3), about 4-5% of all childhood 
cancers in the UK (around 64 children per year) are registered as HL. HL is 
predominant in older children (between 10 to 14 years old) and no infant cases with 
HL are registered so far (12). HL can be successfully treated in the developed 
countries like the UK. However, the mortality rate is high in under-developed 
countries (one in two registered cases), and developing countries (one in four cases) 
(3). 
This disease was first described in 1832 by Thomas Hodgkin (15). A majority of HL 
cases (95%) belong to the classical form of the disease and the remaining 5% are of 
nodular lymphocyte predominant HL (NLPHL). Based on the histology and cellular 
composition, classical HL is subdivided into nodular sclerosis (NS), mixed cellularity 
(MC), lymphocyte-depleted (LD), and lymphocyte-rich (LR) forms. The tumour cells 
in classical Hodgkin’s lymphoma (cHL) are known as the Hodgkin and Reed-
Sternberg (HRS) cells, and in nodular lymphocyte predominant lymphoma (NLPHL) 
they are known as lymphocyte predominant (LP) cells.  Irrespective of the subtype, 
the tumour cells account for only 1-10% of the total cellular infiltrate. This low tumour 
cell content along with poor chromosome morphology has made it very difficult for 
researchers to investigate the molecular events in the development of HL. 
1.1) Molecular biology of Hodgkin’s lymphoma 
Germinal centre (GC) B cells that escape apoptosis after acquiring fatal 
immunoglobulin V gene mutations are believed to give rise to HRS cells. In rare 
cases (~ 2%), HRS cells originate from T cells. On the other hand, LP cells derive 
from antigen-selected GC B cells (2).   
Comparative genomic hybridisation (CGH) was used to detect copy number 
aberrations in HRS cells. Chromosomal arms 1p, 6q, 7q, 11q, 12q, and 14q have 
shown recurrent multiple chromosomal break points. Frequent recurrent gains have 
been observed on chromosomes 2, 5, 9, and 12, whereas, frequent losses are 
reported on chromosomes 13, 21 and Y (9).The genomic instability of the HRS and 
LP cells will depend on the complexity of genetic alterations and poses difficulty in 
identifying the genetic aberrations related to pathogenesis (2).  
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 1.2)  Deregulation of multiple signalling pathways in HRS cells 
In recent years, deregulated expression of several proteins and aberrant activation of 
a number of signalling pathways that are associated with the pathogenesis of HRS 
cells have been identified, namely, the transcription factors (NF-κB, STAT, AP-1, and 
Notch1), multiple receptor tyrosine kinase (RTKs), PI3K,  and MEK/ERK pathways. 
These pathways are vital for the proliferation and survival of the HRS cell phenotype 
(2). 
  1.2.1) Anti-apoptotic mechanisms in HRS cells 
As the HRS cells are derived from pre-apoptotic GC B cells, evading apoptosis is 
vital in the transformation. As mentioned above several signalling pathways are 
aberrantly activated to facilitate the generation of HRS cells, most importantly NF-κB. 
1.2.2) NF-κB pathway activation 
The NF-κB transcription factor family consists of five members, Rel A, Rel B, c-Rel, 
NF-κB1, and NF-κB2, which can act as homo-and/or heterodimers. In the classical 
NF-κB pathway, the p50/p65 dimer was kept in the cytoplasm by binding to IκBα, a 
NF-κB inhibitor. As a result of activating the pathway, IKK (IkB kinase complex) 
kinases phosphorylate IκBα and thereby induce its proteosomal degradation 
resulting in the translocation of NF-κB dimers into the nucleus and which 
subsequently activate multiple target genes. This activation can be partially mediated 
through receptor signalling, such as the TNF family member CD40. Other receptors 
involved in similar NF-κB activation include CD30, TACI, BCMA, RANK and Notch1 
(15).  
However, these signalling pathways are not sufficient for the strong constitutive NF-
κB activation. Several genetic aberrations have been identified in HRS cells that 
affect the NF-κB pathway. The REL gene show copy number gains or amplification 
in 40% to 50% of HL cases (15). The NFKBA gene (which encodes IκBα and IκBε) 
has also been shown to have mutations. Recent studies have shown TNFAIP3 
(Tumour Necrosis Factor, Alpha-induced Protein-3) as a novel tumour suppressor 
gene that is involved in the regulation of the NF-κB pathway. The TNFAIP3 gene 
encodes A20 protein that has ubiquitinase and deubiquitinase functions. A20 is a 
negative regulator of NF-κB signalling and acts upstream of the IKK kinases (15). 
Some of the previous studies on HL described mutations/deletions in this gene in 
30%- 40% of the cases (15-16).  
1.3) TNFAIP3 
TNFAIP3 gene expression is induced by tumour necrosis factor (TNF). TNFAIP3 
encodes a zinc-finger protein, A20, which is known to inhibit NF-κB activation and 
TNF-mediated apoptosis (18).  The TNFAIP3 gene is located on Chromosome 6q23 
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and has 9 exons. Coding sequence of this gene is 2373 nucleotides long, and 
encodes 790 amino acids (20).  
TNFAIP3 mutation seems to have an inverse correlation with the presence of 
Epstein-Barr virus (EBV) in HRS cells. Around 70% of EBV-ve cases showed 
TNFAIP3 mutations (mostly deleterious) where as only 12% of the EBV infected 
patients showed mis-sense mutations inTNFAIP3 gene. This might indicate an 
alternative NF-κB activation mechanism involving A20 inactivation and EBV infection 
(16). Functional studies involving re-expression of A20 in A20 deficient HL cell lines 
resulted in reduced expression of NF-κB target genes and negatively affected cell 
survival, demonstrating that A20 is a tumour suppressor (16). The role of TNFAIP3 
as a tumour suppressor gene has also been demonstrated in other lymphomas, such 
as primary mediastinal B cell lymphoma (PMBL), which are also characterized by 
constitutive activation of the NF-κB pathway, as mentioned above (16). 
For the better understanding of the genetic alterations and their role in the HL 
development, we need to isolate the tumour cells and study the variations across the 
whole genome. 
1.4)  Microdissection method 
Microdissection techniques can be divided into three main categories: manual 
extraction, selective ablation, and laser capture microdissection (LCM). In this study 
we used LCM method to isolate the tumour cells from the fixed cell line samples. 
LCM was first designed by ‘Lance Lotta’ and co-workers in the mid 1990 at the NIH, 
Maryland, USA. There are 3 main types of LCMs, Infrared (IR) LCM, Ultra violet (UV) 
LCM, and a combined version (IR/UV LCM). In the IR LCM method, the surrounding 
tissue of the target specimen were filled with a melted ethylene vinyl acetate (EVA)  
by laser activation and then the target specimen selectively adhere to the 
thermoplastic membrane by low energy laser pulse. The targets are then extracted 
by removing the polymer from the tissue surface. This method uses low energy 
beams so low photo chemical effects on the specimen, although visualization in this 
method is fuzzy. UV LCM method, in contrary, selects and cuts the target specimen 
with a fine laser beam. This method avoids the unwanted debris surrounding the 
specimen and aided with better visualization. We used UV LCM method to 
microdissect the HL cells in our study (31). 
1.5) Whole genome amplification (WGA) 
A single cell usually contains ~6-7 picograms (pg) of genomic DNA (30). Most of the 
sequencing based methods such as whole genome sequencing or exome 
sequencing methods require ~3-5 micrograms (µg) of a good quality starting material 
(DNA) per reaction.  Hence, we need to amplify the genome by more than 1000 fold, 
if we are working on a sample material which contains only few (1-100) cells.  
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Various commercial WGA kits are available to meet the above requirements, such as 
QIAgen’s ‘REPLI-g’, GE Healthcare’s ‘GenomiPhi’, and Sigma’s ‘GenomePlex’. 
These kits work on the either ‘PCR’ or ‘multiple displacement amplification’ (MDA) 
method. PCR-based methods use DNA polymerase from a thermophilic bacterium 
(Thermus aquaticus) and amplify the DNA by repeated ‘denaturation-elongation’ 
steps at various temperatures. MDA method employs ‘bacteriophage (phi 29) DNA 
polymerase’ for the rolling circle amplification of a DNA template at a ‘constant’ 
temperature (isothermal). MDA method is much slower (~18 hours) than the PCR 
based method (~3 hours) (29). 
The above commercial kits facilitate a straight forward application of WGA method to 
generate the necessary quality and quantity of the product.  However, the choice of 
the kit will depend on the research question and the sample material (old, degraded, 
fixed, paraffin embedded and frozen etc.) as the reliability (percentage of samples 
met the requirement), fidelity, and coverage will vary between these technologies.  
For genotyping applications, the longer MDA method (‘REPLI-g‘) found to have 
better ‘accuracy’ and coverage than the faster PCR method (Genomeplex) (29). 
 
1.6) Aim 
In this study, we aimed 1) to establish ‘whole genome amplification method’ that can 
be potentially used in genome sequencing of HL cell lines and HL patient samples; 
2) to confirm genetic changes in the TNFAIP3  gene of HL cell lines discovered by a 
previous study; 3) to investigate whether there are genetic changes in the  TNFAIP3 
gene of HL cell line L540; 4) to investigate whether microdissection and whole 
genome amplification methods will introduce any changes to the genome sequences 
using the KM-H2 and L-591 cell lines by comparing WGA amplified and unamplified 
DNA; and 5) to investigate the applicability of the whole genome amplification 
method to the HL patient samples. 
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2) Materials and Methods 
 
2.1) COSMIC (Catalogue of Somatic Mutations in Cancer) search for the 
frequently mutated genes in Hodgkin’s lymphoma 
COSMIC is a comprehensive database designed to gather, curate, organise, and 
present the information on somatic mutations in cancer and put that information in 
the public domain (23). This database allows researchers to investigate the key 
oncogenes, gene fusions and structural rearrangement annotations across 
numerous cancer samples. COSMIC integrates the manually curated cancer 
mutation data from scientific literature with the output from the Cancer Genome 
Project (CGP) (5). I searched for the genes that are heavily mutated in the Hodgkin’s 
lymphoma in this data base by selecting the type of cancer and the histology subtype 
using COSMIC web interface. 
2.2) Patient samples and cell lines 
This study was part of an ongoing research that has been approved by the National 
Children’s Cancer and Leukaemia Group (CCLG) Biological Studies Steering Group. 
These samples were collected by the tissue bank of the National Children’s Cancer 
and Leukaemia Group (CCLG). Four patient samples that were used in this study 
(labelled as 1.5, 6.4, 7.21 and 7.8) were already fixed and microdissected into ‘PALM 
membrane adhesive cap’ (PALM tubes) (50 cells in each tube) and stored at -200 C.  
Human Hodgkin’s lymphoma cell lines HDLM-2 (DSMZ No: ACC 17), KM-H2 (DSMZ 
No: ACC 8), L-428 (DSMZ No: ACC 197), L-540 (DSMZ No: ACC 72), L-591(DSMZ 
No: ACC 602), and L-1236 (DSMZ No: ACC 530) were obtained from Leibniz 
Institute DSMZ-German Collection of Microorganisms and Cell Cultures, 
Inhoffenstraße 7B, 38124 Braunschweig, GERMANY (11). 
All the 6 cultured HL cell lines, HDLM-2, KM-H2, L-428, L-540, L-591, and L-1236, 
were cultured and kindly provided by Eszter Nagy, a PhD student at Prof. Paul 
Murray’s lab, School of Cancer Sciences, College of Medical and Dental Sciences, 
University of Birmingham, Birmingham, UK. 
2.3) Laser microdissection and pressure catapulting of cells 
Appropriate volumes of cultured KM-H2 (6.25 mL at 8X104 cells/mL concentration) 
and L-591 (1.47 mL at 17X104 cells/mL) were centrifuged at 3000 r.p.m for 5 minutes 
and the pellet was re-suspended with 500 µL Phosphate Buffered Saline (PBS) and 
100 µL of this spun on to membrane-covered slides (PALM) using a Cytospin at 
1000 r.p.m. for 5 minutes. Immediately, the slides were air dried and were fixed 
using cold ethanol and stained with Haematoxylin. This entire procedure was 
performed on ice.  
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Then the slides were air dried and stored at -20°C until the microdissection was 
performed. The slides were then taken to the Human Biomaterials Resource Centre, 
College of Medical and Dental Sciences, University of Birmingham, UK (10), 
samples were microdissected using the PALM microbeam HBO100/AX10 Laser 
Capture Microdissection (LCM) apparatus (Carl Zeiss PALM Microbeam, Carl Zeiss 
Ltd, Cambridge, UK) (27) After calibrating the ‘power and focus’ (Energy = 40, 
Focus= 69, LPC= -20, and Delta = 2), the cells were selected for cutting and 
capturing on to the caps of ‘PALM membrane adhesive cap’ tubes (PALM tubes).  
Figure 1 show how a single cell on the KM-H2 PALM membrane slide was selected 
and captured. The slides were micro-dissected in different batches of a single cell 
and 50 cells onto the cap of PALM tubes. The caps of these tubes were checked 
under the LCM for the presence of cell sections adhered to them. The ‘PALM 
membrane adhesive cap’ tubes with cells were stored at -20°C until they were used 
in the whole genome amplification method. 
 
 
Figure 1. Microdissection of a single KM-H2 cell. A: A single KM-H2 cell was selected; B: 
cut was made; C; image of the membrane section containing the single KM-H2 cell captured on the 
PALM tube cap. The bar in the figures A, B, and C represent scale 15 uM,15 uM, and 25uM 
respectively.   
 
2.4) DNA extraction of the HL cell lines 
All the 6 HL cell lines, HDLM-2, KM-H2, L-428, L-540, L-591 and L-1236 were 
cultured and appropriate volumes of the cell cultures (3X106 cells) spun down and 
their pellet was re-suspended in PBS and sent to the Genomics lab, at the University 
of Birmingham for the DNA extraction (7). 
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2.5) Whole genome amplification (WGA) of the HL cell lines 
Whole genome amplification of the microdissected cells was initially carried out using 
QIAGEN’s REPLI-g Mini Kit (25 X, Catalogue no.150023, 19) according to the 
manufacturer’s instructions. REPLI-g kit works on a principle known as Multiple 
Displacement Amplification (MDA) method where random primers (hexamers) bind 
to the template and generate fragments at a constant temperature with the help of a 
high fidelity DNA polymerase enzyme, usually ‘Φ29 DNA polymerase’. The resulting 
fragments of DNA are larger than conventional PCR products and with lower error 
frequency. 
However, the REPLI-g Mini Kit didn’t give consistent amplification of the 
microdissected cell material.  As an alternative, GenomePlex® Single Cell Whole 
Genome Amplification Kit (WGA4) from Sigma-Aldrich, UK (7) was used for whole 
genome amplification from the microdissected cells. WGA4 works on a principle of 
‘non-enzymatic random fragmentation of the genomic DNA’ (28). The WGA was 
performed according to the manufacturer’s instructions. After the lysis procedure 
tubes that contained cell(s) were again checked under the microscope for the 
presence of cells on their caps to ensure the cells were lysed and ‘off’ their caps. 
 
2.6) PCR   
PCR primers designs were taken from a study by Roland Schmitz et al. (16) and 
used for the PCR and sequencing reactions (Supplementary Table 1). These primers 
have a melting temperature (Tm) ranging between 55°C and 74°C. Primers were 
ordered from Sigma-Aldrich, at 100 µM concentration (24). The primer stocks were 
diluted with nuclease free water as per the requirement (100 picomoles/µL for PCR, 
and 3.2 picomoles/ µL for sequencing reactions).  The diluted primers and the stocks 
were stored at -20°C. 
PCR was set up using QIAGEN’s multiplex PCR Kit for a total of 20 µL reaction 
mixture according to manufacturer’s instructions. Hot start PCR was programmed as 
follows: 95°C for 5 minutes (Denaturing of DNA) followed by 35 cycles of 94°C for 45 
seconds, 65°C for 1 minute (Annealing) and 72°C for 1 minute (Extension) and then 
the final extension at 72°C for 10 minutes.  
The PCR product was then validated by running 6.0 µL of the product and 3.0 µL of 
100bp ladder from Invitrogen, UK (Catalogue.No.15628-019) on a 1.5% Agarose gel. 
The bands were checked for approximate length of the product for each set of 
reaction (Supplementary Table 2). 
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2.7) PCR product purification 
ExoSAP-IT for PCR Product Clean-Up (catalogue no. 78200 200 UL), Affymatrix, 
UK, was used to clean up the PCR products according to the manufacturer’s 
instructions. The concentration of the clean PCR product was measured by loading 
1.0 µL on the Nanodrop 1000 spectrophotometer (Thermo scientific, USA).  
2.8) Sequencing  
Clean PCR products were then diluted to the appropriate concentration (as 
requested by the Genomics lab) in a total of 10 µL reaction volume (Supplementary 
table 3) and sent to the sequencing service facility at Genomics lab, University of 
Birmingham, UK. These samples were later loaded on to the ABI 3730 Sequencing 
machine at the Genomics lab. 
2.9) Sequence Analysis 
Sequences retrieved from the Genomics lab, University of Birmingham, for the cell 
lines and patient sample were in the .ab1 format (format for the raw DNA data taken 
out from a scientific instrument and output from Applied Biosystem’s Sequence 
Analysis software). All these files were aligned and edited with the genomic 
reference sequence, (NCBI Reference Sequence: NC_000006.11, 
gi|224589818:138188581-138204449, 21) using ‘Sequencher 5.0 Demo’ 
software(17).  
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3) Results  
 
3.1) COSMIC search of frequently mutated genes in Hodgkin’s 
lymphoma 
COSMIC database was searched for the key cancer genes associated with 
Hodgkin’s lymphoma. The search yielded the top 20 genes most frequently mutated 
in the HL patient samples, namely SOCS1, TNFAIP3, NRAS, TP53, CYLD, HRAS, 
KDM6A, CDKN2A, CDKN2a(p14), BCR, ETV6, PCM1, NPM1, KRAS, JAK2, ATM, 
BRAF, PIK3CA, PTEN, and WT1. Of these 20 genes 3 genes were found to be 
mutated in higher percentage of patient population in which they were tested; 
namely, TNFAIP3, SOCS1, and NRAS (Figure 2). A literature review on the 
importance of these genes in HL was carried out to select a single gene for our 
study. All of these genes are important in the HL disease development. However, 
TNFAIP3 gene was selected on the basis of its central role in HL development and 
its location on 6q23 (this region is frequently deleted in B cell lymphomas). SOCS1 is 
located on chromosome 16p13.13 and the genomic instability in this region is not 
implicated in the HL development, so far.  
 
Figure 2. Genes frequently mutated in Hodgkin’s lymphoma. The red bar represents 
total number of samples and the blue bar represents the number of samples with mutations (Source: 
23). 
3.2) PCR of TNFAIP3 exons using unamplified genomic DNA 
Test PCR reactions were set up with A20 E2F/E2R primers on all the six cell line 
DNA (Figure 3_1), and with all the TNFAIP3 gene primers on unamplified L-591 cell 
line to obtain optimal PCR conditions (Figure 3_2). Another PCR reaction was set up 
with all the primer sets for unamplified KM-H2 cell line sample. The PCR products 
were run on a 1.5% agarose and checked for the bands at the appropriate size 
(Supplementary Table 2).  
As mentioned in some of the previous studies (16), a deletion of a region between 
intron 2 and exon 6 in the TNFAIP3 gene was observed in the unamplified sample of 
the KM-H2 cell line in this study (Figure 3_3).  
This PCR method was repeated for the rest of the cell line and for the whole genome 
amplified KM-H2 and L-591, with all the TNFAIP3 gene primer sets until we obtained 
PCR product with appropriate band size. 
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Figure 3. Gel images of the PCR experiments. 1. A-F: exon 2 PCR products (462 bp) for 
HDLM-2, KM-H2, L-428, L-540, L-591, and L-1236 cell lines respectively; G,H: exon 7 and 9 PCR 
products for HDLM-2; NTC: non-template control; 2. L-591 genomic DNA PCR. Numbers 2, 3, 4/5, 6, 
7.1, 7.2, 8, 9 represent the corresponding TNFAIP3 exon PCR products for L-591 genomic DNA with 
band  sizes, 462, 306, 588, 311, 568, 653, 328, and 527 respectively (Supplementary table 2) ; 3. The 
PCR using the KM-H2 genomic DNA shows exon 3 to 6 are missing. 
3.3) Whole genome amplification 
Microdissected sections on the ‘PALM tubes’ caps were checked before and after 
the whole genome amplification procedure, to ensure the capture and lysis of the 
cells. Whole genome amplification of microdisected samples containing a single KM-
H2 cell section, and 50 L-591 cells section was carried out using REPLI-g mini kit.  
Products of the WGA were run on a 2% agarose gel (Figure 4).  
 
Figure 4. Images of a single KM-H2 cell, and 50 L-591 cells WGA products is showed. A: 
REPLIi-g kit successfully amplified KM-H2 cell genome, NC: non template control; B:  REPLI-g failed to amplify 
50 L-591 cells. However, the gDNA (positive control) was amplified. NTC: non-template control.  
REPLI-g kit was inconsistent in whole genome amplification process of other cell 
samples with a single cell and 50 cells (Figure 4), and often showing positive results 
for the non template control (NTC) in the reactions. 
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As an alternative, SIGMA’s GenomePlex Single Cell Whole Genome Amplification kit 
(WGA4) was used in the whole genome amplification of microdissected cell line (KM-
H2 and L-591) and patient (1.5, 6.4, 7.21, and 7.8) samples (Figure 5) according to 
the manufacturer’s instructions. The amplified products were run on a 2% agarose 
gel. WGA4 kit amplified all the samples. 
 
Figure 5. KM-H2, L-591 and patient samples amplification using WGA4 kit.  A: 10 cells and 50 
cells of KM-H2; a single cell and 50 cells of L-59; PC: positive control; NC: non-template control; B: patient 
samples 1.5, 6.4, 7.21, and 7.8; PC: positive control; NTC: non-template control.  
3.4) Whole genome amplification – PCR 
A test PCR with the WGA4 products of KM-H2 (10 cells, 50 cells) and L-591 (a 
single cell and 50 cells) microdissected samples was set up using the exon 8 
primers. Only the PCR for WGA4 product of L-591 microdissected sample with 50 
cells has worked (Figure 6_1).  
To rule out the possibility, that, this PCR failure could have been due to the lower 
amount of initial DNA template concentration, another PCR test  was set up with 
various template concentrations (0.5, 1.0, 2.0, 3.0, and 4.0 µL)  of WGA4 products 
with the exon 8 primers. In this experiment WGA4 products of KM-H2 (10 cells, 50 
cells) and 50 L-591 cells microdissection sample have worked. The L-591 single cell 
WGA4 product again failed to amplify this region (Figure 6_2). 
 
17 
 
Figure 6. Test PCR on WGA4 products of KM-H2 and L-591 samples. 1. A test PCR with the 
WGA4 products of KM-H2 (10 cells, 50 cells) and L-591 (a single cell and 50 cells) microdissected samples was 
set up using the exon 8 primers. NC (WGA): non-template control from WGA4 experiment; NC (PCR): non-
template control for this PCR experiment; 2. A test PCR with various template concentrations (0.5, 1.0, 2.0, 3.0, 
and 4.0 µL) of KM-H2 (10 cells and 50 cells) and L-591 (a single cell and 50 cells) WGA4 products; NC (WGA): 
non-template control from WGA4 experiment; NC (PCR): non-template control for this PCR experiment. 
PCR on WGA4 product of L-591 for all of the TNFAIP3  exons were successful 
(Figure7_1:A) and the PCR experiments on WGA4 product  of KM-H2 yielded  the 
same results as those of cell lines, such as the deletion in the region between intron 
2 and exon 6 (Figure7_1:B). 
WGA4 was used to amplify some Hodgkin’s lymphoma patient samples, namely, 1.5, 
6.4, 7.21 and 7.8 (50 cells each). The amplified products were run on a 2% agarose 
gel (Figure 7_2). PCR experiments on patient samples 1.5, 7.4 and 7.8 were failed 
(Figure7_2:A). However, patient sample 6.4 successfully PCR amplified all the exons 
except exon 7.1(Figure7_2:B).  
 
Figure 7. PCR on WGA4 products of KM-H2, L-591, and patient samples. 1. PCR on the WGA4 
products of KM-H2 (50 cells) and L-591 (50 cells) microdissected samples was set up using all the exon primers. 
NC (WGA): non-template control from WGA4 experiment; NC (PCR): non-template control for this PCR 
experiment. 2. PCR on patient sample WGA4 product. A: WGA4 products for patient sample 1.5 and 7.21 have 
failed in the PCR; B: Patient sample 6.4 has picked up bands for all the exons except 7.1. NC: negative control; 
g-DNA:  positive control. 
3.5) Quality of DNA sequences from unamplified cell lines and amplified 
cell lines and patient samples 
The quality of the sequences was assessed based on the percentage of the 
alignment (in Sequencher 5.0 software) between sequence traces obtained and the 
reference sequence. The quality of sequences for the unamplified cell lines was 
better (79.7%) than those of WGA sequences (76.5%) (Table1).  Good quality 
sequences obtained for the rest of the unamplified cell lines (HDLM-2, L-428, L-540, 
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and L-1236) cell lines. Interestingly, the quality of the sequences obtained from the 
patient sample 6.4 were as good as the unamplified cell line samples (Table 2).   
Table 1. Showing the quality of sequences for the unamplified and WGA KM-H2 and L-591 
  KM-H2 L591 
 
PCR 
product 
(bp) 
WGA 
(bp) 
 PASS (%) 
UA 
(bp) 
PASS (%) 
WGA 
(bp) 
PASS (%) 
UA 
(bp) 
PASS (%) 
Exon 2  462 473 63 1270
a
 75 387 79.8 389 73.5 
Exon 3 306 del del del del F F 1215
c
 71.4 
Exon 4-5 588 del del del del 600 81.2 559 85.5 
Exon 6 311 del del del del 301 80.7 301 81.7 
Exon 7.1 568 561 83 1099
b
 82 545 91.6 543 91.9 
Exon 7.2 653 F F F F F F F F 
Exon 8 328 333 59.5 317 81 301 79.4 301 71.5 
Exon 9 528 515 87.6 533 79.4 508 54.7 513 83.8 
          
bp:base pairs; UA:unamplified; del:deletion; F:sequencing failure/poor quality sequences; a: exon7.1 
IntR  to exon 2; b:Int ex7; c: exon 3 IntF to exon 5 
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Table 2. Showing the quality of sequences for the unamplified and patient sample 
 PCR 
product 
(bp) 
L-428 L-540 L-1236 HDLM-2 
Patient (6.4) 
sample 
 
UA 
(bp) 
 PASS 
(%) 
UA 
(bp) 
 PASS 
(%) 
UA 
(bp) 
 PASS 
(%) 
UA 
(bp) 
 PASS 
(%) 
UA 
(bp) 
 PASS 
(%) 
Exon 2  462 477 73 477 71.9 477 71.7 481 70.7 F F 
Exon 3 306 278 87 283 86.2 282 85 282 79.8 278 88.8 
Exon4-5 588 566 91.5 569 90.5 569 91.2 598 88.3 561 86.8 
Exon 6 311 290 84 300 81.7 293 83.3 291 82 FP FP 
Exon 
7.1 
568 547 91.6 545 94 544 93.8 549 92 FP FP 
Exon 
7.2 
653 637 84 639 85 636 90.4 642 89.1 629 93.5 
Exon 8 328 303 88.8 302 90.4 301 87 300 88.7 299 91 
Exon 9 528 512 88.7 512 88.9 513 89.9 512 88.9 500 94.6 
            
bp:base pairs; UA:unamplified; del:deletion; F:sequencing failure/poor quality sequences; FP:PCR 
failure 
3.6) Comparison of WGA amplified and unamplified DNA sequence 
To investigate whether microdissection and whole genome amplification methods will 
introduce any changes to the genome sequences, exon sequence of TNFAIP3 gene 
of WGA amplified and unamplified DNA from the KM-H2 and L-591 cell lines were 
compared. No sequence differences were found. 
3.7) Analysis of the TNFAIP3 mutations in HL cell lines and patient 
sample 
All of the seven nucleotide changes that were observed in this study were illustrated 
in the Table 3. Nucleotide T deletion was observed at the base position 8751 (intron 
5-6) (gi| reference sequence) in L-540 and L-591 (both unamplified and WGA 
amplified) (Table 3).  
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Figure 8. Chromatograms showing nucleotide changes observed in the cell lines and 
patient samples. The chromatogram shows A.  T446G transversion for the L-591 (unamplified) cell line, B. 
G491A transition for the L-1236 cell line, C.  A1434T transversion for the patient 6.4;  and D. C8751A 
transversion for the L-591 and L-540 cell lines. 
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Some of the nucleotide changes observed in this study match with the previous 
studies on the HL cell lines (16), such as the deletion of the region between intron2 
and exon 6 in the KM-H2 cell line, and mutation in L-591 at coding base 491 
(G491A) which has changed the amino acid Tryptophan to STOP codon. A1434T 
transversion and T3003A transitions were observed in the patient sample 6.4. 
 
Mutations observed in L-1236 (G491A) and patient sample 6.4 (A1434T) were 
searched (http://siftdna.org) for potential implication on the protein function. The 
results show that both of these mutations are ‘novel’ with tolerated (A1434T) and 
damaging (G491A) effect. We could not obtain population frequency for any of the 
genetic changes observed in this study.  
Table 3. Mutations found in cell lines and patient sample 
Sample EBV Subtype 
Nucleotide 
change a 
Amino acid 
change b 
  
   
  
KM-H2 (B) − NS Δ intron 2–exon 6 Frameshift aa 99 
L-540 (g) − NS C8751Ac Intron 5-6 
L-1236 (g) + NS G491A W142STOP 
L-591 (B) + NS C8751Ac Intron 5-6 
 Patient 6.4 − − A1434T T463S 
Patient 6.4 − − T3003A 3' UTR 
 
NS: Nodular Sclerosis; MC: Mixed Cellular; Δ: deletion; g: unamplified; B: found in both amplified and 
unamplified; a: position on the coding sequence (22); b: corresponding to PDB accession 
no.NP_006381; c: corresponding to the genomic reference sequence, (NCBI Reference Sequence: 
NC_000006.11, gi|224589818:138188581-138204449 (21). 
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4) Discussion 
 
In this study, we initially used REPLI-g kit to whole genome amplify the cell line 
samples. However, due to inconsistencies in the amplification results and unspecific 
amplification of samples, we replaced it with the WGA4 kit. WGA4 kit amplified DNA 
of all the microdissected cell lines samples and patient samples. However, WGA 
products for patient samples 1.5, 7.28, and 7.8 failed to amplify all of the TNFAIP3 
exons in the following PCR experiments. Patient sample 6.4 amplified all of these 
exons except the exon 6 and 7.1.  
Better quality sequences were obtained for the cell line (>76.5%) and patient sample 
6.4 (90.9%).  WGA method gave good coverage for the TNFAIP3 gene in these 
samples. However, sequencing reactions for exon 3 (L-591) and exon 7.2 (KM-H2 
and L-591) had consistently failed. 
 After analysing the mutation spectra for the whole genome ‘amplified’, and 
‘unamplified’, KM-H2 and L-591 cell lines, we came to a conclusion that 
microdissection and whole genome amplification methods didn’t introduce any 
changes to the sequences. However, differences in the quality of the sequences 
obtained and the failure to generate sequences for all the exons for these amplified 
samples had hampered our investigation.  
Our study for the first time revealed C8751A transversion in the TNFAIP3 gene for 
the L-540 cell line. The same mutation was observed in the L-591 cell lines in this 
study. 
Our results were compared to a previous study (16) that looked into the mutation 
spectra for the TNFAIP3 gene in the same cell lines.  We observed same nucleotide 
changes in the cell lines KM-H2 (deletion of intron 2– exon 6 region), and L-1236 
(G491A). However, improvement in the quality of the sequence and the coverage for 
the region of interest in the WGA products will result in a better whole genome or 
exome sequencing of the target sample.  
The functional role of the genetic changes observed in our study was investigated in 
http://siftdna.org. The results show that the mutations observed in L-1236 (G491A) 
and patient sample 6.4 were ‘novel’ with tolerated (A1434T) and damaging (G491A) 
effect. We could not obtain population frequency for any of the genetic changes 
observed in this study.  
This study enabled us to amplify DNA from very few numbers of cells (~50 cells) 
which will be sufficient enough to use in the future exome/ whole genome 
sequencing applications to understand the role of genetic alterations in Hodgkin’s 
lymphoma.  
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6) SUPPLEMENTARY NOTES 
 
Table 1. Primer sequences used for genomic DNA amplification of TNFAIP3 
Primer name                   Sequence  
Amplification     
of 
A20E2exF  TGCCTACAGATCAGGGTAATGACAAG  exon 2 
A20E2NewexF  GGAGTCGTATTAAAGTCAGGCTAA exon 2 
A20E2NewexR  GGCAAAAGAAACACAACAGAAC exon 2 
A20E2intF  GTTTCCTGCAGGCAGCTATAGAGG exon 2 
A20E2R  AGCTTCATGAATGGGGATCCAGCAG  exon 2 
A20E3exF  ACCATTCAGTCCCCTAGAATAGCAG  exon 3 
A20E3intF  ACCTTTGCTGGGTCTTACATGCAG  exon 3 
A20E3R  TATGCCCACCATGGAGCTCTGTTAG  exon 3 
A20E4-5exF  TGAATAATTGTAGAGTGATGTCAGAATGAC exon 4/5 
A20E4-5intF  TACAGGGAGTACAGGATACATTCAAGC  exon 4/5 
A20E4-5R  GGAAAACCCTGATGTTTCAGTGTCTAG  exon 4/5 
A20E6exR  AATCACTCTACTGTTGAGCTTCAGG  exon 6 
A20E6F  TGAGATCTACTTACCTATGGCCTTG  exon 6 
A20E6intR  TCAGGTGGCTGAGGTTAAAGACAG  exon 6 
A20E7.1exF  GGTTCTACAATTCTTGCCATAATCCAC  exon 7 
A20E7.1intF  GAGCTAATGATGTAAAATCTTGTGTGTG  exon 7 
A20E7.1R  CAAAATCCGTTGTGCTGCACATTCAG  exon 7 
A20E7.2exR  CAGTTCTGCCTGACTGCCTACATG  exon 7 
A20E7.2F CTCTCGGGGAGAAGCCTATGAGC exon 7 
A20E7.2intR  GAACAAAACCCCTTCTGGACAGCAG  exon 7 
A20E8exR  ATGAGGAGACAGAACCTGGCAGAG  exon 8 
A20E8F  ACTGTCAGCATCTCTGTATCGGTG  exon 8 
A20E8intR  TGTCACTGTCGGTAGAAAACGCTC  exon 8 
A20E9exF  GTAGACTCCACACTCTCCAATGAG exon 9 
A20E9intF  GTGCTCTCCCTAAGAAATGTGAGC  exon 9 
A20E9R  GGGTTACCAAACCTGAGCATCGTGC  exon 9 
A20E9Rnew  CGGGTTACCAAACCTGAGCATCGTG exon 9 
   
E2-E9:exon2-exon9; F:forward primer; R: reverse primer. 
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Table 2. List of the primers used and their PCR products  
Primer name  
Position on 
gDNA  
Product 
(bp) 
A20 E2intF->E2R  3690->4152 462 
A20 E2NewF->E2NewR  3712->4110 398 
A20 E3intF->E3R  7336->7642 306 
A20 E4-5intF->E4-5R  8193->8781 588 
A20 E6intF->E6R  9875->9914 311 
A20 E7.1intF->E7.1R  10918->11486 568 
A20 E7.2intF->E7.2R  11966->12012 653 
A20 E8intF->E8R  12888->12925 328 
A20 E9intF->E9R  13522->14049 527 
A20 E9intF ->E9Rnew         13522->14050 528 
E2-E9:exon2-exon9; F:forward primer; R: reverse primer; gDNA: genomic DNA. 
 
 
Table 3. Template requirements for sequencing at the Genomics lab 
Template DNA  DNA Quantity (ng) 
single-stranded DNA 25-50 (*) 
double-stranded DNA 150-300 (*) 
PCR : 100-200 bp 1-3 (**) 
PCR : 200-500 bp 3-10 
PCR : 500-1000 bp 5-20 
PCR : 1000-2000 bp 10-40 
PCR : >2000 bp 20-50 (*) 
 (*) :  for BigDye® Terminator versions 1.0, 2.0 and 3.0 higher quantities necessary 
(**) :  rule of thumb: PCR product length (in bp) / 50 = amount in ng. 
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Abstract 
 
Adrenocortical carcinoma (ACC) is a heterogeneous malignancy with an incident 
rate of about 0.7-2.0 cases per million people per year. However, it accounts for 
more than 15% of the total adrenal incidentalomas registered every year. 
Distinguishing malignant ACC from benign Adrencortical Adenoma (ACA) has been 
a major problem. Hence, in this study we attempt to statistically design a biomarker 
tool based on steroid metabolic excretion data from ACA and ACC patients. Data in 
question is of 32 distinct adrenal derived steroid secretions obtained from 102 ACA 
patients and 45 ACC patients. Variable selection was performed by forward 
selection, backward search, stepwise selection, and all subset combination methods 
using logistic regression. An investigation into prediction model building was carried 
out and an assessment was made on the model fitness using various criteria, such 
as log-likelihood, deviance, AIC, and Wald’s statistics. Sensitivity and specificity for 
some of the best models was evaluated using ROC curve. Some of the best 
prediction models from all subset combination models were chosen to inspect all the 
patient samples in the data. Models with 6, 7, and 8 variable subsets were shown to 
have best prediction capability with perfect sensitivity and specificity. However, 
investigation into these variable subsets revealed ‘overfitting’. Models with 4 and 5-
variable subset combinations have relatively high prediction capability with a 
significant sensitivity and specificity (AUC=99.3% and AUC=99.8%, respectively). 
The strength of the estimates in these models was relatively stable when compared 
to 6-8 variable subset models.  
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1) Introduction 
 
Adrenal tumours are one of the most prevalent forms of cancer with an incident rate 
of 2% in general population and about 7% in the older generation (70 years or above 
age groups). Incidental discovery of Adrenal tumour (Adrenal incidentalomas) during 
computed tomography (CT) and autopsy resulted in a rapid increase in their 
prevalence rate (1, 8, and 12). Adrenal tumours cause serious health problems in 
patients, such as Cushing’s syndrome, Conn’s syndrome (hyperaldosteronism), 
virilisation in females, feminisation in males, and multiple endocrine neoplasia (MEN) 
(1, 3, 8, 12-13). 
 
Adrenal tumours can be divided into two groups based on their origin, 
‘Adrenocortical adenoma’ (ACA) and ‘Adrenocortical carcinoma’ (ACC) of Adrenal 
Cortex origin, and ‘Neuroblastoma’ and ‘Pheochromocytoma’ of Adrenal Medulla 
origin. The majority of adrenal tumours are benign, but still cause some serious 
health problems. Only 10% of the Pheochromocytomas and all ACC are malignant. 
ACC is an aggressive form of cancer which can occur in all age groups (1, 8, 12).  
 
Most often ACC are not diagnosed, until they have grown very large and/or 
metastasize to other organs, due to their location deep in the retro peritoneum. 
Surgical removal of ACC is carried out as part of the main treatment but is not 
feasible with many patients, due to complications associated with the hormonal 
imbalances after surgical removal of the tumour. It is very difficult to distinguish ACC 
from ACA based on histopatholgical and biochemical methods. Some of the imaging 
techniques, such as [18 F] Fluorodeoxyglucose positron emission tomography, offer 
better diagnostic capability with higher specificity (91%) and sensitivity (97%) (13). 
But this technology is very expensive and sparsely available. Hence, it is pivotal to 
differentiate ACC from ACA by some other means.   
1.1) Evidence based medicine  
 
Traditionally, medicine has been very much subjective. This trend has been 
changing in recent years, where ’evidence based’ medicine is gaining popularity 
among physicians and health policy makers. Evidence based medicine can be best 
explained as ‘a conscientious, explicit and judicious use of current best evidence in 
making decisions about the care of individual patients’. Clinical prediction models 
may provide the evidence based input by providing estimates of the individual 
probabilities of risks and benefits. Clinical prediction models consider a number of 
characteristics related to the disease, patient and the treatment (7).  
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Prediction models may help design preventive interventions for patients with high 
risk of having or developing a disease. From a clinical point of view, prediction 
models may provide valuable information to patients and their physicians on the 
probability of a diagnosis or a prognostic outcome. 
 
1.2) Statistical modelling for prediction 
 
In data analysis, statistical models summarise patterns in the data. Prediction mainly 
estimates risks of disease development and survival rates for the patients. Prediction 
also tests hypotheses, such as the importance of certain predictor variables in a 
disease and the correlation between variables (14).  
 
Statistical model for Prediction can be distinguished into 3 main classes: regression, 
classification, and neural networks according to Ewout W. Steyerberg (10). However, 
majority of other statisticians discern the prediction modelling methods into two 
classes: Regression analysis (for continuous variables) and classification (for non-
continouos variables). Regression analysis investigates the relationship between a 
‘dependent/outcome’ variable and one or more ‘independent/predictor’ variable(s) by 
employing several techniques for modelling and analysis. Dependent/outcome 
variable can be defined as the observable result, such as the presence or absence 
of cancer, when any one of the independent variable is manipulated (5). Independent 
variables are usually the measurements of an effect, such as response to 
treatment/drug, and effect of temperature on durability of materials. Regression 
helps understand how the value of a dependent variable changes with changes to 
any one of the independent variables (10).  
 
Classification method identifies a set of categories/sub-populations to which a new 
observation belongs, based on ‘training set’ of data containing observations whose 
category membership is known. The individual observations are analysed into a set 
of quantifiable properties, known as explanatory variables, features etc. These 
properties may be of categorical, ordinal, integer valued, or real valued. Neural 
networks can be considered as the non-linear extensions of linear logistic models. 
The generalised non-linear models (GNLM) are implemented as neural networks. In 
this method, outcome is related to the non-linear combinations of the predictor 
variables, in contrast to the methods where the outcome is related to simple linear 
combination of estimated regression coefficients and predictor values (14).  
 
For binary outcome such as the diagnostic outcome (presence or absence of a 
disease) there are several methods available for prediction modelling. Logistic 
regression facilitates as a quite flexible model to derive predictions. In this approach, 
interactions and nonlinearity can be incorporated. Other models such as Naive 
Bayes can be seen as a simplified version of logistic regression, which ignores 
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correlations between predictors. The choice of the model depends on various 
factors, such as the sample size and research question(s) (14). 
 
This study used logistic regression models to distinguish ACC from ACA patients in 
the data. 
 
1.3) Logistic regression 
 
Logistic regression is a flexible method as it can incorporate categorical and 
continuous variables, non-linear transformations, and interaction terms. Logistic 
regression is a form of ‘generalised linear models’. Similar to linear regression 
model, the binary outcome ‘Y’ is linked to a linear combination of a set of predictors 
and regression coefficients ‘β’ (4). Logistic ‘link’ function is used to restrict predictions 
between ‘0’ and ‘1’.  
 
Logistic regression works by relating the log odds (logit) to a linear combination of 
the explanatory variables. Logistic regression was applied to predict the 
transformation of the outcome (otherwise we could predict unrealistic values of the 
probability ( i.e. outside 0 to 1 range). Log odds value lies between minus infinity and 
plus infinitive. Logistic regression can be interpreted using odds and odds ratio as 
below,  
 
Therefore,   loge (odds) =   a+bx 
Where, ‘a’ is an intercept where predictor variable x=0, ‘b’ regression coefficient that 
relate to ‘x’, and ‘e’ is the base of natural logarithm.  
In the case of one predictor variable ‘P’ the logistic regression equation from which 
the probability of outcome is predicted is given by: 
 
In logistic regression, estimates of the coefficients are obtained in an iterative 
procedure known as ‘maximum-likelihood’. 
 
 
10 
 
Maximum likelihood is generally used to estimate βi regression coefficients in a 
standard logistic regression model. βi regression coefficients  can be interpreted as 
the effect of a 1-unit increase in ×i  while keeping the other predictors in the model 
constant. In logistic regression model,   βi is unadjusted or univariate for a single 
predictor, but with multiple predictors, βi is adjusted or conditional on the values of 
other predictors (14). 
 
1.4) Building prediction models 
 
In the development of prediction models some important considerations have to be 
made. The very first and the most important one is the ‘research question’. Some of 
the other important questions that need to be addressed are: What do we know 
about the predictors? How are the predictors in the study defined? What is the 
outcome?  How to deal with the missing values? The other important considerations 
involve coding of the predictors, specifying a model, ‘overfitting’, and validation of the 
model (14). 
1.4.1) Coding 
 
As in many cases the raw data is often not in an appropriate form for entering in the 
regression models. Hence, they need to be manipulated. This process is called 
‘coding’. Data analysis usually starts with obtaining an impression of the data. This 
includes finding the missing values and the distribution of the predictors. Descriptive 
analyses, such as frequency distribution and Inter-quartile (IQ) range are quite useful 
to find the distribution of predictor variables in the data (14). 
1.4.2) Model selection 
 
Selection of the predictor variables can also be made based on the subject 
knowledge.  The list of the number of variables in the study can be reduced by a 
literature review. Variables can be selected based on their distributions. Variables 
with relative importance can be deleted if they have a large number of missing 
values (14). 
 
Variables are often strongly correlated with each other. This ‘collinearity’ is one of the 
major ‘variance inflation factors’, which degrades the precision of estimate 
coefficients (11). The number of variables in a model must not depend only on the 
statistical significance but also on the number of questions it will answer. A 
parsimonious model is not necessarily a better model, as it might not answer all the 
biological research questions. However, it can be the case when pre-specified 
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models were compared. A model with smaller number of variables is easier to 
interpret and practice. 
 
Validation of the prediction models on new subjects, outside the subjects on which 
they were built, is the main aim of outcome prediction. A major threat to this 
validation is ‘Overfitting’, where predictions are not valid for the new subjects even 
though the data under study are well described. These models might have been built 
by capitalising on the specifics and idiosyncrasies of the sample (9). ‘Overfitting’, can 
also be defined as the ‘curse of dimensionality’, or as fitting a statistical model that 
has too many degrees of freedom (10). As a result of overfitting, too ‘optimistic’ 
impression of a model will be achieved in new subjects from the underlying 
population. Optimism = True performance (underlying population) - Apparent 
performance (estimated performance in the sample) (14). 
1.5) Challenges involved in statistical prediction modelling 
 
Statistical prediction modelling faces various challenges, such as model uncertainty, 
and limited sample size.  
 
Model uncertainty arises when a model is not fully pre-specified, before fitting it to a 
data set. Iterative model checking and model modifications are often followed in this 
case. On the other hand, standard statistical methods assume that a model was pre-
specified. Hence, parameter estimates such as regression coefficients, their 
corresponding standard errors, 95% confidence intervals, and p-values are largely 
unbiased. When structure of the model was at least partly based on findings in the 
data, bias may occur, and usually the uncertainty of conclusions drawn from the 
model is underestimated (2, 6). 
 
A large sample size is necessary to address most of the scientific questions with 
empirical data. In the majority of the prediction studies ‘effective sample size’ is 
much smaller than indicated by the total number of subjects in a study (9). For 
example, a study containing 1000 patients with an event incidence rate of 1% will 
have an effective sample size of 10. We may not be able to derive a reliable 
prediction model from a small sample size. A large sample size is desirable to study 
several aspects of prediction modelling, such as gene-disease associations and 
multivariable prognostic modelling. A small size renders in making strong modelling 
assumptions. With a small samples size we may have to assume the linearity of the 
predictor variable and no/less correlation between the predictor variables. Hence, we 
may have a limited power to test the deviations from these model assumptions. 
Sample size may restrict our scientific approach and may dictate on what we can 
achieve as more complex questions, such as ‘what are the most important predictors 
in the model?’ can be solved with a large sample data (14, 15). 
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1.6) Aim of the study 
 
This study was aimed at designing prediction models by using the differences in the 
steroid and steroid metabolite excretion levels between the ACC and ACA patients.  
In this study we investigated and compared different methods for selecting variables. 
We also aimed to investigate statistical significance of the estimates in the prediction 
models and examine the estimates for these models on all of the patients in the data. 
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2) Material and Methods 
 
2.1) Patient data 
 
The data used in this study was provided by Wiebke Arlt group from ‘Centre of 
Endocrinology, Diabetes, and Metabolism, University of Birmingham, Birmingham, 
UK’. The data contains urinary steroid metabolomes, analysed in a single run by gas 
chromatography/mass spectrometry (GC/MS), of 24 hour urine samples from 
adrenal tumour patients. These samples were collected, with informed consent, in 
six specialist referral centres participating in the European Network for the study of 
Adrenal Tumours (ENS@T; www.ensat.org) between 2006 and 2009. Appropriate 
ethical approval was obtained from the local ethical boards. These samples were 
identified as either benign ACA or malignant ACC with the help of histological, 
biochemical, clinical examination as well as imaging.  
 
Wiebke Arlt group have used the same data to design a biomarker tool by applying 
‘Generalized Matrix Learning Vector Quantization (GMLVQ)’ method to differentiate 
ACC from ACA. They have published their research findings in ‘Journal of Clinical 
Endocrinol Metab’, in 2011(17).  This group have also used logistic regression 
method, but concluded GMLVQ was a better method for building prediction models 
with this data set. In this study, I have made an attempt to learn and apply logistic 
regression method to build alternative prediction models.  
 
The data in the present study contains 32 predictor variables. These variables were 
grouped into Androgen metabolites, Androgen precursor metabolites, 
Mineralocorticoid metabolites, Mineraloccorticoid precursor metabolites, 
Glucocorticoid precursor metabolites, and Glucocorticoid metabolites, based on their 
biochemical nature. The detailed description of these 32 variables is available in the 
Supplementary Table 2.  
2.2) Coding 
 
The data taken from the Wiebke Arlt group’s study (17) was labelled as ‘raw data’ 
and the predictor variables in the raw data were labelled from P1 to P32. Data was 
manipulated by replacing any ‘0’ values with ‘0.5’, so that when log transformed, the 
patient measurements with ‘0’ values were not denoted as ‘NA’. Log transformation 
expands the smaller values and squeezes the bigger values thus making the 
distribution more symmetric. Predictor variables in the log-transformed changed data 
were labelled from s1 to s32. The mean values observed for the log-transformed 
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changed data were less than that of the log transformed raw data. Best variables 
from both forms of the data set were taken to build prediction models. 
2.3) The Logistic regression model for binary responses 
 
A logistic regression model helps us to predict the probability of a particular outcome 
in relation to a list of predictor (independent) variables. In our study, the outcome has 
two categories. The predicted value lies between ‘0’ and ‘1’ (in this study, ‘0’ 
represents the presence of Adrenocortical adenoma (ACA) and 1 represents 
presence of Adrenocortical carcinoma (ACC). Hence, Binary logistic regression was 
applied. The outcome variable will be the proportion (probability) of individuals with 
the characteristic (i.e., ACC or ACA). This approach is a form of ‘discriminant’ 
analysis. 
2.4) Data was processed using R language 
 
The majority of statistical problems in this study were performed using R language 
on R platform (R version 2.13.1 and R Commander version 1.7-3). All of the 
functions run in R were obtained from the ‘Comprehensive R Archive Network 
(CRAN) (16).The scripts that were used to perform the statistical analysis were 
detailed in the Supplementary Table3. 
2.5) SPSS 
 
IBM SPSS software was used to generate prediction models using ‘stepwise forward 
selection’ method and ‘stepwise backward search’ method.  
2.6) Stata 
 
Stata V11.0 was used to generate ROC curves using the ‘lroc’ command following 
fitting the logistic models.  
2.7) Bluebear 
 
‘Bluebear’ cluster is a parallel computing service provided by the ‘IT services’ at the 
University of Birmingham, Birmingham, UK. It consists of 1500 processing cores and 
approximately 150 terabytes of user disk space with a sophisticated cluster 
computing system. Computationally intensive, all subset combinations method was 
performed using logistic regression on Bluebear platform. This method generated 
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subset combinations that had significant values for assessing measure of fit, such as 
‘deviance’ and ‘AIC’. 
2.8) Building prediction models 
 
In the previous sections, I have estimated and interpreted the coefficients in the 
logistic regression model. To build a ‘best prediction model’ for distinguishing ACA 
from ACC using the dataset, I needed to devise a strategy to  a) select predictor 
variables for the model , and b) employ a set of methods to assess ‘fit’ of  the models 
by analysing the estimates in the prediction models. 
2.8.1) Variable selection 
 
One of the aims in this study is to build the most parsimonious prediction model that 
still can describe the data. Prediction models with less number of variables can be 
numerically more stable and more easily generalized.  Addition of more variables to 
the prediction model will increase the estimated standard errors and as a result the 
prediction model becomes dependent on the observed data. This approach can lead 
to ‘over fitting’ of the prediction model, where idiosyncrasies in the data are fitted 
rather than the ‘generalizable’ patterns. As a result, this model is not applicable to 
new patients.  
It is important to include the relevant variables in the prediction model, to gain as 
much control of confounding as possible within the given data set. But, care must be 
taken for not ‘over fitting’ the model. This can be very real in our case as the number 
of variables is relatively large compared to that of patients. 
In this study, potentially important variables were selected based on their estimated 
coefficients, estimated standard error, the likelihood ratio test for significance of the 
coefficient, and Wald statistic. There are various techniques available for choosing 
variables for a regression model. One of the popular methods that can be used to 
build prediction models is generalized linear regression, which employs ‘forward 
selection’, ‘backward elimination’, ‘stepwise regression ’, and ‘best subsets 
selection’(Supplementary Table3). 
a) Forward selection 
 
Forward selection is one of the simplest data-driven prediction models building 
approach, where variables are added one at a time. The ‘significance’ of the variable 
is a measure of the statistical significance of the coefficients for that variable. In 
logistic regression, the significance is assessed with the help of likelihood ratio chi-
square test. Hence, at any single step in the procedure, the most ‘significant’ variable 
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will produce the greatest change in the log-likelihood as compared to a model not 
containing the variable. The ‘significance’ of the variables is usually tested based on 
a pre-set P-value. The conventional P-value set up is at 0.05, but can choose a 
customary P-value level at say 0.10 or 0.15, to explore the nature of this method (4).  
 
The model building starts with adding the most ‘significant’ variable to an empty 
model. Then at each step, each variable that is not already in the model is tested for 
the inclusion in the model. The most ‘significant’ of these variables is added to the 
model, so long as its P-value is below the pre-set level. This method is iterated until 
none of remaining variables are ‘significant’ when added to the model.  This multiple 
use of hypothesis testing nature can lead to higher ‘type 1 error rate’ for a variable, 
where an ‘unnecessary’ chance is given for a variable inclusion. Because of this 
error prone nature, forward selection is usually a very good exploratory method (4). 
In forward selection, each addition of a variable to a model can also render one or 
more of the variables in the model ‘insignificant’ due to their ‘correlation’ with each 
other.  
b) Backward elimination 
 
In this method, an initial screening of the variables for their ‘significance’ is done 
based on the pre-set P-value. Then a model is fitted with all the variables of interest. 
Then at each step, the least ‘significant’ variable is excluded based on the pre-set P-
value. This procedure is repeated until we end up with a model containing all the 
‘significant’ variables. 
 
But, this model building approach can omit a variable in the initial steps which can be 
a very ‘significant’ variable to include in the final reduced model. This flaw can be 
avoided by using the ‘stepwise regression’ method. 
c) Stepwise regression 
 
Stepwise regression method is a bidirectional selection method, which uses both 
forward selection and backward elimination. The model either starts with an empty 
model or a full model and the predictor variables are selected either for inclusion or 
exclusion from the model in each step based entirely on statistical criteria. Missing 
values restrict the number of available cases to this method, especially, when a full 
model is employed.  
d) All subset combinations 
 
An alternate method is to fit all possible regression models, and to evaluate these 
models according to some criterion, such as deviance or AIC. In this method a 
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number of best regression models can be selected. However, the fitting of all 
possible regression models is very computer intensive and time consuming. 
2.9) Criteria for model fitting 
 
Log-likelihood, Deviance, AIC, and Wald’s statistics were used to assess the fit of 
the prediction model. 
2.9.1) Log likelihood ratio 
 
The log likelihood ratio (LLR) corresponds to a difference in log likelihoods. LLR is 
maximum at the maximum-likelihood estimate (MLE) and equals zero. MLE is the 
value that corresponds to the largest possible likelihood of the event (π) 
Log (LR) = L(π)-L(MLE) 
 
Log-likelihood indicates how much unexplained information is there after the model 
has been fitted. The deviance statistic -2LL is a goodness of fit indicator.  Large 
values of log-likelihood indicates poor fitting. Log-likelihood can be used to compare 
the state of logistic regression model against baseline state. A baseline state is when 
there is only the constant in the prediction model. 
 
   
Where, ‘R’ is simple model and ‘F’ is a complex model (usually has an extra 
variable). The parameters in the simple model must be a proper subset of the 
parameters in the complex model. This model follows   distribution with k degrees 
of freedom where k is the number of predictors in the new model.  was used to 
test whether addition of a variable will reduces the goodness-of-fit measure.  
2.9.2) Akaike Information Criteria (AIC) 
 
Akaike Information Criteria (AIC) is used to measure the relative ‘goodness of fit’ of a 
prediction model. This criteria work on the basis of trade off between ’accuracy’ and 
‘complexity’ of the model. 
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The general equation for AIC can be given as below, 
 
Where, ‘k’ is the number of parameters in the model and ‘L’ is the maximum value of 
likelihood function for the estimated model. 
The model with the least AIC value is considered as a better model. AIC includes a 
penalty for increasing the number of estimated parameters. This would discourage 
‘over fitting’ (increase in the parameters improves goodness of fit, regardless of the 
parameters used in generating the data). 
2.9.3) Assessing the contribution of predictors (Wald’s statistics) 
The contribution of a predictor can be assessed by Wald statistics (z). Wald statistics 
is defined as the coefficient of the predictor (b) divided by the standard error (SE) of 
the coefficient, b/SE(b).  
2.10) Area under the curve (AUC) 
 
Area under the curve, otherwise known as the area under the receiver operating 
characteristic (ROC) curve, is one of the traditional measures for binary and survival 
outcomes. It’s a visualisation method for discriminant analysis. ROC curve plots the 
sensitivity (true positive rate) against the 1-specificity (false positive rate) for 
consecutive cut-offs for the probability of an outcome. A model with AUC=1 is a 
perfect model with greater specificity and sensitivity. AUC=0.5 is as good as 
guessing (15). 
2.11) Correlation test  
 
Correlation is a method of analysis for association between two continuous 
variables. The degree of ‘association’ is measured by ‘correlation coefficient (r)’.  
Pearson product-moment correlation coefficient 
 
This is a standard method of measuring the association between variables. This 
method leads to a quantity called ‘r’ which can take any value from -1 to +1, r=0 
means no correlation, and r=1 means perfect correlation. This correlation coefficient 
‘r’ measures the degree of ‘straight line’ association between the values of the two 
variables. Pearson’s correlation coefficient between two variables is defined as the 
covariance of the two variables divided by the product of their standard deviations. 
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3) Results 
 
3.1) Data analysis 
 
Initial interrogation of the data revealed that it is  positively skewed with some 
missing values (total 57, all of them in ACC patients), 0 (total 13, mostly in ACC 
patients), 1(total 16, mostly in the ACA patients) with a highest measured value of 
812807 (for variable P3 in patient 10) (Table1).  We employed logistic regression 
method in our study which makes no ‘assumptions’ on the distribution of the data. 
Table1.  Raw data containing ‘zeroes’ and ‘missing values’ 
Variable Missing ‘Zero’ value 
P3   1(139) 
P5 1(10)   
P6 1(1)   
P9 2(11,15) 1(30) 
P10   1(30) 
P11 11(1-4,10-16) 2(34-35) 
P12 7(1-4,10,11,15) 4(45,48,59,73) 
P13 10(1-4,10-15)   
P15 11(1-4,10-16) 2(24,34) 
P18 3(12,13,14) 1(96) 
P21 10(1-4,10-15) 1(34) 
P32 1(1)   
Predictor variables in the raw data with missing values and zeroes (the corresponding 
patient number in parentheses). 
To study the distribution of the predictor variables in the data, the median and 
quartiles were calculated (Table2). The median and IQR values for these predictor 
variables were found to be larger in the ACC patients. Figure1 shows the difference 
in distribution between the ACC and ACA patients. IQR values for ACC were found 
to be significantly larger than in ACA. This will further strengthen our theory, that 
steroid and steroid metabolite excretions vary significantly between ACC and ACA 
patients.  
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Table2. IQR and median values for the predictor variables 
     MEDIAN  IQR 
Variable Common name  ACC ACA ACC ACA 
P1 An  1130 632 1898 802.75 
P2 Etio  3671 803.5 6029 791 
P3 DHEA  612 58 15725 111.75 
P4 16α-OHDHEA 653 201.5 2566 278.25 
P5 5-PT  1900.5 121 7292.5 91.25 
P6 5-PD  3412 257 13460.5 231.5 
P7 THA  112 93.5 137 110.5 
P8 5α-THA  76 88 114 66.75 
P9 THB  147 105 308.5 101.25 
P10 5α-THB  155 221.5 275 182.25 
P11 3α5β-THALDO 24 22 36.25 20 
P12 THDOC  102.5 15.5 184.75 16.5 
P13 5α-THDOC  22 4 53.5 4.75 
P14 PD  839 137.5 2262 120 
P15 3α5α-17HP  18.5 9.5 31.25 16.75 
P16 17HP  511 120 658 172.25 
P17 PT 1484 372.5 3215 513.25 
P18 PTONE  32 18.5 86.25 24.75 
P19 THS  2151 122 4346 103.25 
P20 F  245 85 534 73.75 
P21 6β-OH-F  356 133 1176 127.75 
P22 THF  2836 1811 3791 1143 
P23 5α-THF  852 1264.5 1174 1412.5 
P24 α-cortol  557 355.5 1289 272.25 
P25 β-cortol  740 536 1018 414.5 
P26 11β-OH-An  653 552.5 1520 512.75 
P27 11β-OH-Et  366 265 1479 316.75 
P28 E 164 126 250 98.5 
P29 THE  3701 3478.5 4638 2577.25 
P30 α-cortolone  1840 1340 1899 783.25 
P31 β-cortolone  677 665.5 813 516 
P32 11-oxo-Et  483.5 401 1623.25 455.75 
      
Common names of the variables in the study and their distribution in ACC and ACA patients 
are shown here. Inter quartile range (IQR) in ACC patients are showing higher values. 
 
Steroid profiling of the samples revealed the differences between ACA and ACC 
patients (Table2, Figure1). Higher excretion of active androgens (An and Etio) and 
androgen precursor metabolites (5-PD, DHEA, and 16α-OHDHEA) were observed in 
ACC. In mineralocorticoid precursor metabolites, only THDOC and 5α-THDOC show 
elevated levels of excretion in ACC. ACC also showed increased levels of 
Glucocorticoid  precursor metabolites (PD, PT, and 17-HP), and Glucocorticoid 
metabolites (THS, THE, 6β-OH-F, and α-cortol) excretion when compared to ACA 
(Table2, Figure1).  
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Figure 1. Inter quartile range (IQR) for predictor variables in ACC and ACA 
patients. The Blue and Red columns represent ACC and ACA patients in the study respectively. 
 
Analysis of the sum of steroid subclass metabolites had revealed elevated levels of 
glucocorticoid metabolites excretion in 82% of ACC, compared to only 29% of ACA. 
An excess of androgen precursor, either combined with elevated levels of 
glucocorticoid precursors (36%) or both glucocorticoid and mineralocorticoid 
precursor (33%) was seen in the majority (67%) of ACC patients. In 9% of the ACC 
and 1% ACA patients, isolated glucocorticoid precursor excess was observed. In 2% 
of ACC and ACA patients elevated levels of isolated androgen precursor metabolites 
was observed. No excessive levels of isolated androgen metabolite were found. 
There was no effect of age, sex, tumour size, or presence of metastasis on the level 
of metabolic excretion observed, in these ACC and ACA patients (Weibke Arlt et al). 
3.2) Coefficients of the predictive variables 
3.2.1) Raw data 
 
Coefficients of the predictive variables in the raw data were analysed using R 
(Table3).  Estimations for coefficients were made on both raw data and log 
transformed changed data based on log-likelihood ratio, Akaike Information Criteria 
(AIC), Deviance, p-value and Wald’s statistics. Based on log-likelihood ratio of the 
variables, P19, P5, P6, P13, P2, P21, P12, P17, P14, and P3 have significant 
predictive capabilities. However,   the order of significance based on the p-value and 
deviance was P5, P6, P19, P2, P13, P17, P14, P3, P16, and P4 (Table3).  
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Based on AIC criteria, the order of significance obtained was P5, P6, P19, P13, P2, 
P21, P12, P17, P14 and P3. These four selection methods yielded the same five 
highly significant predictive variables at the top of the table.  However, Wald’s 
statistics [Pr(>|z|) ]  yielded P2, P5, P13,  P16, P17, P6, P12, P14, P24, and P19 
variables with significant predictive capability (Table3). The differences in the output 
can be due to the differences in the way they trade off statistical significance with the 
number of parameters (as in case of AIC).   
3.2.2) Log form of changed data 
 
Raw data was manipulated by replacing ‘0’ value with ‘0.5’ so that when log 
transformed the patient measurements with ‘0’ values were not denoted as ‘NA’. The 
analysis of log transformed changed data revealed that the most significant variables 
for log-likelihood, deviance, p-value, and AIC were the same, namely, s19, s5, s14, 
s6, s16, s17, s2, s3, s4, and s20 in the order of most significance first. However, for 
Wald’s statistics the most significant variables, although identical to the other 
methods, were yielded in a different order: s14, s19, s5, s6, s2, s16, s17, s3, s4, and 
s20 (Table3).  
3.2.3) Comparing the coefficients of raw and log transformed data 
 
The estimates of the coefficients from raw data and log transformed changed data 
were then analysed to check which scale of the data has most significant predictor 
variables. The investigation revealed estimates for coefficients for predictor 
variables, s10, s12, s14, s16, s17, s20, s21, and s23 from the log-scale were more 
significant than their counterparts in the raw data. A new predictor data set (Best 
data set) was designed which is a concoction of the most significant predictor 
variables from both scales (Table3). Best data set was used in the prediction 
modelling. 
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Table 3.  Coefficients for Raw data and log transformed data 
Raw data Log transformed changed data 
Var 
Wald's    
p-value  AIC 
Change in 
Deviance Var 
Wald's    
p-value AIC 
Change in 
Deviance 
P1 < 0.0001 167.1 17.99 s1 < 0.001 173.32 11.78 
P2 < 0.0001 117.64 67.45 s2 < 0.0001 128.76 56.33 
P3 < 0.0001 138.71 46.38 s3 < 0.0001 139.67 45.42 
P4 < 0.0001 142.39 42.7 s4 < 0.0001 148.52 36.57 
P5 < 0.0001 81.89 100.82 s5 < 0.0001 110.58 74.52 
P6 < 0.0001 90.58 92.13 s6 < 0.0001 121.06 64.03 
P7 0.0548 181.41 3.69 s7 0.2634 183.84 1.25 
P8 0.2951 184 1.1 s8 0.3862 184.34 0.75 
P9 < 0.001 169.46 10.83 s9 0.9875 185.09 0 
P10 0.1669 183.18 1.91 s10 0.0507 181.27 3.82 
P11 0.1115 154.42 2.53 s11 < 0.0001 168.19 16.91 
P12 < 0.0001 126.39 41.32 s12 < 0.01 176.99 8.1 
P13 < 0.0001 99.83 59.88 s13 < 0.01 176.05 7.57 
P14 < 0.0001 137.11 47.99 s14 < 0.0001 116.33 68.76 
P15 < 0.001 143.78 13.17 s15 0.3367 184.17 0.92 
P16 < 0.0001 140.54 44.55 s16 < 0.0001 123.16 61.93 
P17 < 0.0001 129.42 55.67 s17 < 0.0001 123.74 61.35 
P18 0.019 172.34 5.5 s18 0.4318 184.48 0.62 
P19 < 0.0001 98.27 86.83 s19 < 0.0001 99.978 85.12 
P20 < 0.0001 165.88 19.21 s20 < 0.0001 159.03 26.06 
P21 < 0.0001 124.57 35.14 s21 0.5764 184.78 0.31 
P22 < 0.0001 168.45 16.64 s22 < 0.001 171.63 13.46 
P23 0.571 184.77 0.32 s23 0.0115 178.7 6.39 
P24 < 0.0001 161.1 23.99 s24 < 0.0001 164.63 20.46 
P25 < 0.001 171.96 13.13 s25 0.0247 180.05 5.05 
P26 < 0.0001 167.53 17.56 s26 0.0156 179.25 5.84 
P27 < 0.0001 164.36 20.73 s27 0.0156 179.24 5.85 
P28 < 0.01 176.15 8.94 s28 0.0102 178.49 6.6 
P29 0.0165 179.35 5.74 s29 0.4242 184.45 0.64 
P30 < 0.01 177.11 7.98 s30 0.2222 183.6 1.49 
P31 < 0.01 176.95 8.14 s31 0.4004 184.39 0.71 
P32 < 0.0001 163.71 19 s32 0.3732 184.3 0.79 
 
Estimates for the predictive variables from the raw data and log transformed changed data 
was shown in the table.  Var: predictor variables  
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3.3) Model fitting 
 
The predictor variables were selected by employing logistic regression using various 
statistical approaches, such as forward selection, backward search, stepwise 
selection, and all subset selection methods. These methods were performed on R, 
SPSS, and Stata software platforms as mentioned in the materials and methods 
section. 
3.3.1) Forward selection 
 
Forward selection method was performed in the SPSS software as I was having 
algorithm convergence problems in R. Stepwise forward selection had fitted s12, 
s17, s20, and s23 variables into a model (Table4).  
 Table 4. Variable equation in forward selection 
Variables in the Equation 
              OR CI 
  B S.E. Wald Sig. OR 
Lower 
limit 
Upper 
limit 
Lower 
limit 
Upper 
limit 
Step 
1a 
s12 1.786 0.323 30.515 0 5.968 3.17 11.24 1.153 2.419 
Constant -7.572 1.229 37.99 0 0.001         
Step 
2b 
s12 2.06 0.351 34.491 0 7.847 3.94 15.61 1.372 2.748 
s23 -1.047 0.306 11.684 0.001 0.351 0.19 0.64 -1.647 -0.447 
Constant -1.398 1.965 0.506 0.477 0.247         
Step 
3c 
s12 1.574 0.369 18.224 0 4.825 2.34 9.95 0.851 2.297 
s17 1.193 0.468 6.487 0.011 3.297 1.32 8.25 0.276 2.11 
s23 -1.312 0.35 14.028 0 0.269 0.14 0.53 -1.998 -0.626 
Constant -5.513 2.699 4.174 0.041 0.004         
Step 
4d 
s12 1.242 0.38 10.675 0.001 3.461 1.64 7.29 0.497 1.987 
s17 1.412 0.505 7.806 0.005 4.104 1.53 11.04 0.422 2.402 
s20 0.623 0.309 4.074 0.044 1.865 1.02 3.42 0.017 1.229 
s23 -1.549 0.396 15.329 0 0.212 0.1 0.46 -2.325 -0.773 
Constant -7.223 2.956 5.97 0.015 0.001         
a. Variable(s) entered on step 1: s12; b. Variable(s) entered on step 2: s23; 
c. Variable(s) entered on step 3: s17; and d. Variable(s) entered on step 4: s20. 
3.3.2) Backward search and bidirectional search 
 
Backward and bidirectional search in R yielded the same predictor variables in  the 
model and failed to fit full 32 variable models in all the software I used in the study. 
Algorithms in these programs software did not converge. This can be blamed on the 
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smaller number of events (45) compared to the number of predictor variables. 
Hence, this method cannot be applied in our study (Table 5). Backward and 
bidirectional search yielded a model with 18 variables (P2 + P4 + P5 + P8 + P11 + 
P13 + P15 + P18 + P19 + P22 + P26 + P27 + P28 + P31 + s10 + s12 + s20 + s21) 
with an AIC value of 38.  
Table 5. Bidirectional search method 
Step  Deviance AIC 
 Intercept 7.76 36.45 
+ s12 9.03 55.09 
+ s10 8.91 53.23 
+ P31 8.76 50.95 
+ P2 8.65 49.33 
+ P22 8.56 47.79 
+ P5 8.44 45.86 
+ P27 8.42 45.57 
+ P4 8.37 44.82 
+ P19 8.28 43.36 
+ P13 8.28 43.28 
+ P28 8.28 43.26 
+ P18 8.23 42.46 
+ P8 8.15 41.15 
+ P15 8.14 41.01 
+ s21 8.13 40.91 
- P6 7.76 38.45 
- P30 7.75 38.39 
- P25 7.75 38.39 
- s23 7.75 38.38 
- P29 7.75 38.35 
- P3 7.75 38.34 
- P24 7.75 38.34 
- P9 7.75 38.32 
- P7 7.75 38.23 
- P32 7.74 38.22 
- P1 7.72 37.87 
- s16 7.72 37.86 
- s14 7.72 37.85 
+ P26 7.94 37.60 
- s17 7.71 37.58 
+ s20 7.92 37.28 
+ P11 7.90 36.97 
‘+’addition of the variable to the model;’ -‘ is deletion 
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3.3.3) All subset combinations (from best data set) 
 
This was a CPU intensive approach, where all the possible subset combinations 
were calculated from the 32 variables. Logistic regression analysis was carried out 
on the best data set raw data using ‘Generalized Linear Model’ (GLM) method in R. 
A script was written to obtain subsets containing 2 to 8 variable set combinations 
using the ‘Bluebear’ (Supplementary Table 3). This method resulted in the subset 
combinations which had significant values for the assessing measure of fit such as 
‘deviance’ and/or ‘AIC’.  
The time scales given below were for running the ‘glm’ (generalized linear model) 
script that was on a regular desktop. The script for 2-variable subset models yielded 
496 combinations in less than 10 minutes. Best of these combinations was (A): P5 + 
P19, with deviance=57.5 and AIC=63.5.The script for 3-variable subset yielded 4960 
different combinations in less than 30 minutes. The most significant model derived 
from the 3-variable subset combination was (B): P5 + P19+P31, with deviance=39.8 
and AIC=47.8(Table 6). 
35,960 4-variable subset combinations were calculated, and the output was 
produced in less than 3 hours. The predictive significance in these models had 
improved significantly as compared to 2, 3-variable subset models, with the best 
model (C): P2+P19+ s21+P31. There were 201,376 different 5-variable subset 
models that can be obtained from 32 variables in 10 hours. The best model in these 
combinations was (D): P2+P6+P11+P19+P31 (Table 6). 
The ‘glm’ script for 6-variable combination subset took more than 40 hours to run. 
So, for the variations in this script and for the large numbered (7 and above) variable 
subsets, the scripts were run in R on the ‘Bluebear’ platform. The script for 6-variable 
subset models returned 906,192 with the most significant model (E): 
P2+P6+P19+s21+P25+P30. The predictive capability has significantly increased for 
these models (Table 6). 
The scripts for 7 and 8-variable subset model returned 3,365,856 and 10,518,300 
combinations respectively. The best models for these combinations were 
(F):P2+P6+P19+s21+P22+P25+P30,and (G): P2+P3+P6+P15+P19+P22+P25+P30, 
respectively. These scripts took around 40 hours each to return the results on the 
Bluebear.  
The significance of the model subsets increased with the increase in the number of 
variables in the model in all the subset combinations with deviance. However, the 
significance measure ‘AIC’ increased up to 6 variable subset model and then started 
declined on addition of further variables to the model (Table 6).  
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Table 6.  Best 3 models from each subset combination  
V1 V2 V3 V4 V5 V6 V7 V8 Deviance  AIC 
2 6 19 21 28 31 
  
0 14 
2 6 11 19 25 30 
  
0 14 
2 6 19 21 25 30 
  
0 14 
2 6 11 19 22 25 29 
 
0 16 
2 6 15 19 22 25 30 
 
0 16 
2 6 19 21 22 25 30 
 
0 16 
2 6 17 19 21 22 25 30 0 18 
2 3 6 15 19 22 25 30 0 18 
2 3 6 19 21 22 25 30 0 18 
2 6 11 19 31 
   
13.256 25.256 
2 6 13 19 31 
   
14.179 26.179 
2 6 19 21 31 
   
14.247 26.247 
2 19 21 31 
    
24.281 34.281 
6 19 21 30 
    
24.625 34.625 
2 13 19 31 
    
25.073 35.073 
5 19 31 
     
39.832 47.832 
5 19 30 
     
39.977 47.977 
6 19 30 
     
40.089 48.089 
5 19 
      
57.521 63.521 
5 23 
      
59.007 65.007 
1 5             63.268 69.268 
The coefficients (deviance and AIC) of the best 3 models from each subset combination was 
shown here. V1 to V8 are variables 1 to 8 in the model. The change in deviance has 
improved significantly with the addition of an extra variable. However, AIC value degraded 
with the addition of an extra variable to the 6-variable subset model. 
Investigations on the significance of estimates for each predictor variable were 
carried using the best prediction model of each subset combination. 
 
3.4) Area under the ROC curve 
 
The area under the receiver operating characteristic (ROC) curve was used to 
measure the discrimination and visualize the sensitivity and specificity of the 
prediction models in the study. The ROC curves for the best models from 2-8 
variable subsets (A to G) and forward selection model were drawn. The sensitivity 
and specificity for 2-variable subset was found to be 94%. A similar sensitivity and 
specificity (AUC= 94.8%) was found for the stepwise forward selection model 
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(s12+s17+s20+s23). The measurements for the sensitivity and specificity has 
increased with the addition of each variable, 3-variable subset (97.8%), 4-variable 
subset (99.3%), 5-variable subset (99.8%), and attained a perfect 100% sensitivity 
and specificity from 6-variable subsets onwards (Figure2).  
 
Figure 2.  Area under the ROC curve values for 2-variable (A) through to 7-
variable (G) subset models (as mentioned in the Section 3.3.3) and forward 
selection model (H).  
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3.5) Correlation among the best predictive variables 
 
 3.5.1) Best predictor variables from the subset models 
Best predictor variables were investigated by checking the most frequent variables in 
the best subset models. An investigation into the 12 best models from the 2 to 8 
variable subsets was carried out to find the most frequent variables in these best 
models subsets. As depicted in Figure 3, the most frequent variables in these best 
subset models were, P2, P5, P6, P11, P15, P19, s21, P22, P25, P30, and P31.  
 
Figure 3. Frequencies of the variables in 2-8 variable subset models were shown 
here. Here, bar diagrams A-G are showing the variable frequencies in 2-8 variable subsets.  
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3.5.2) Correlation 
 
An investigation on the correlation among the best predictive variables was carried 
out. Strong association between the predictor variables will undermine the 
significance for the estimates and also result in the inflation of variance. Analysis 
revealed high correlation among variables from the same steroid group as compared 
to the other steroid types. Predictor variable P2 has higher correlation with P6, P22, 
and s21. Variables P5, P3 and P6 have high correlation with each other. P6, P2, P5, 
and P3 were highly correlated. Similarly, predictor variables P22, P25, P31, P30, 
s21, and P2 had high correlation with each other (Table 7&8).    
Table 7. Pearson product-moment 
  P2 P3 P5 P6 P11 P15 P19 P22 P25 P30 P31 
P2 
           P3 0.44 
          P5 0.4 0.71 
         P6 0.57 0.51 0.54 
        P11 0.28 0.19 0.32 0.18 
       P15 0.37 0.02 0.19 0.36 0.1 
      P19 0.32 0.31 0.2 0.39 0 0.15 
     P22 0.56 0.07 0.16 0.27 0.15 0.16 0.14 
    P25 0.56 0.12 0.18 0.33 0.23 0.2 0.22 0.91 
   P30 0.36 0.05 0.18 0.3 0.26 0.27 0.25 0.78 0.77 
  P31 0.49 0.01 0.13 0.33 0.18 0.2 0.09 0.87 0.88 0.83 
 s21 0.55 0.17 0.29 0.44 0.27 0.32 0.23 0.69 0.65 0.72 0.63 
Significant correlations were highlighted in yellow (high) and red (low) colour. The identical half of 
the table was trimmed to make it look more aesthetically appealing 
 
Table 8. Pair-wise p-values 
  P2 P3 P5 P6 P11 P15 P19 P22 P25 P30 P31 
P2 
          
  
P3 < 0.00001 
         
  
P5 < 0.00001 < 0.00001 
        
  
P6 < 0.00001 < 0.00001 < 0.00001 
       
  
P11 0.0011 0.0249 < 0.0001 0.0373 
      
  
P15 < 0.00001 0.8369 0.0308 < 0.00001 0.2281 
     
  
P19 0.0002 0.0002 0.0206 < 0.00001 0.9954 0.0843 
    
  
P22 < 0.00001 0.3933 0.0583 < 0.0016 0.0852 0.066 0.099 
   
  
P25 < 0.00001 0.1604 0.0365 < 0.00001 < 0.01 0.0184 0.0108 < 0.00001 
  
  
P30 < 0.00001 0.597 0.0403 0.0003 < 0.01 < 0.01 < 0.01 < 0.00001 < 0.00001 
 
  
P31 < 0.00001 0.9094 0.1344 < 0.00001 0.0366 0.0224 0.2774 < 0.00001 < 0.00001 < 0.00001   
s21 < 0.00001 0.0549 0.0007 < 0.00001 < 0.0013 < 0.0001 < 0.01 <0.00001  < 0.00001 < 0.00001 < 0.00001 
P2 to s21 were predictor variables from the best models. The identical half of the table was 
trimmed to make it look more aesthetically appealing. 
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3.5.3) Inspection of predictor variables from each subset 
 
The prediction capability of the best model from each subset was analysed with the 
help of ‘scatter plot’ graph (Figure4). When these models were validated on each of 
the patients in the data set, a clear variation in the predictive capabilities between 
these models was found.  Variable subsets 2, 3, 4 and 5 showed inconsistency in the 
predictive capability. However, variable subsets 6, 7, and 8 showed a perfect 
prediction capability. 
 
Figure 4.  Scatter plot depicting the model fit for each patient. Each scatter plot show 
fitness of a subset model on each the patient measurements in the data (number 1-45 are ACC 
patients, P=1, and patient number 46-147 are ACA patients P=0). The subset model represented here 
is the best model (A-G) from each variable subset. 
The estimates for the best predictor variables from all the subset models were 
obtained by logistic regression. These estimates were then standardized by dividing 
the predictor variable measurements with their respective Inter Quartile Range (IQR) 
values. The strength of the predictor variable estimates was examined starting from 
their own estimates and throughout the model building procedure. A good model will 
have its estimates gaining/losing gradually in this process. A sudden multi-fold hike 
or drop can be a result of ‘overfitting’. 
The strength of the estimates was found to be unstable with the addition of a variable 
to 5-variable subset model, as it is evident in the case of P19, where the significance 
of the estimate increased gradually up to 5 variable subset,  a sudden 19 fold  
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increase in the 6 variable subset model, and a 75% drop in the strength of estimate 
in the 7 variable subset. The strength of the estimates for individual predictor 
variable in the majority of subset models was random as well. This phenomenon of 
‘overfitting’ can be blamed on the small sample size, interaction, and collinearity 
(Table 9). 
Table 9. Inspection of predictor variable’s estimates in each subset model 
 
Intercept Estimate IQR A B C D E F G 
P5 -3.11 2.17 414.00 1.70 2.83 
     P19 -2.47 1.20 381.00 0.93 2.99 5.93 11.44 197.09 47.36   
P31 -1.45 0.40 560.00 
 
-3.63 -6.96 -22.02       
P2 -2.76 1.57 1339.00 
  
4.21 8.84 128.99 66.09 83.21 
s21 -7.20 1.29 1.14 
  
0.87   28.83 26.31   
P6 -2.90 1.61 641.00 
   
2.71 66.22 63.55 64.07 
P11 -1.34 0.14 22.00 
   
-2.03       
P25 -1.49 0.44 543.00 
    
-187.28 -179.79 -196.57 
P30 -1.58 0.47 1089.00 
    
-170.32 -201.90 -120.34 
P22 -1.44 0.38 1967.00 
    
  130.39 141.01 
P3 -1.52 0.36 433.00 
    
    -6.22 
P15 -1.72 0.57 19.50 
    
    -24.08 
 
The estimates for each predictor variables in the best model from each subset were 
analysed. Here, IQR, Inter Quartile Range, A is 2-variable subset: P5+P19, B is 3-variable 
subset: P5+P19+P31, C is 4-variable subset: P2+P19+s21+P31,  D is 5-
variablesubset:P2+P6+P11+P19+P31, E is 6-variable subset: 2+P6+P19+s21+P25+P30,  F 
is 7-variable subset: P2+P6+P19+s21+P22+P25+P30, and G is 8-variable subset: 
P2+P3+P6+P15+P19+P22+P25+P30. 
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4) Discussion 
 
Analysis of urinary steroids and steroid metabolite data from adrenal tumour patients 
revealed that some of the steroids and steroid metabolites have a distinct secretion 
pattern between ACC and ACA patients. In ACC patients, a significantly higher 
excretion of An, Etio (active androgens), 5-PD, DHEA, 16α-OHDHEA (androgen 
precursor metabolites), THDOC, 5α-THDOC (mineralocorticoid precursor 
metabolites) PD, PT, 17-HP, THS (Glucocorticoid precursor metabolites), THE, 6β-
OH-F, and α-cortol (Glucocorticoid metabolites) was observed when compared to 
ACA (Table1&Figure1).  
This study was aimed at designing a biomarker tool by exploiting the differences in 
steroid and steroid metabolites excretion levels between ACC and ACA patients. The 
choice of the statistical method, regression analysis, was made basing on some 
criteria, such as the performance of the method, distribution of the data, missing 
values, sample size, and expertise. 
Logistic regression analysis revealed that some of the variables have higher 
predictive capability. However, the order of significance was slightly different 
depending on the measurement criteria, for example, log-likelihood, deviance, p-
value, and AIC criteria gave s19 (THS), s5 (5-PT), s14 (PD), s6 (5-PD), s16 (17HP), 
s17 (PT), s2 (Etio), s3 (DHEA), s4 (16α-OH DHEA), and s20 (F)  in the order of most 
significance first. However, for Wald’s statistics the most significant variables, 
although identical to the other methods, were yielded in a different order: s14, s19, 
s5, s6, s2, s16, s17, s3, s4, and s20 (Table3). The differences in the output can be 
attributed to the random presence of large measurement values for the predictor 
variables in the data, which renders Wald’s statistics insignificant (type2 error) (13). 
This study used stepwise regression methods and all subset combination for fitting 
the models. Among stepwise regression methods, only forward selection method has 
worked with this data. Forward selection method fitted s12, s17, s20, and s23 
variables into a model. This model has a significant sensitivity and specificity 
(AUC=94.8%). However, a thorough investigation into the strength and stability of 
model estimates, interaction and collinearity between variables, and validation on a 
new data set is required.  Backward selection method failed to fit any models as the 
number of events in the study is only 45 (ACC=45) and there were 32 predictor 
variables to fit. A large sample would have been ideal for the application of other 
testing methods. 
Among the methods employed, all subset combination methods yielded most 
parsimonious models with better statistical significance (Table5). However, this 
method is computationally intensive and will require more time and high performance 
computing, such as cluster computing. Inspection of subset models on each of the 
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patient sample in the data revealed an increase in the predictive capability with the 
increase in the number of variables (Figure2&4, Supplementary table 3).  The 
sensitivity and specificity measure for these models using ROC curve showed a 
perfect predictive capability in the larger subset models (from 6-variable subset and 
above) (Figure 2). However, an investigation into the significance of estimates in 
each model revealed a possible ‘overfitting’ in these models. 
Among the subset models 4 and 5-variable subset models showed a significant 
prediction capability with a sensitivity and specificity (AUC) measure of 99.3 % and 
99.8%. The strength of the variable estimates in these models remained stable 
throughout the process. However, a closer examination into the ‘collinearity’ and 
‘interaction’ between the predictor variables in the model is necessary. 
Backward and bidirectional search yielded a model with 18 variables (P2 + P4 + P5 
+ P8 + P11 + P13 + P15 + P18 + P19 + P22 + P26 + P27 + P28 + P31 + s10 + s12 
+ s20 + s21) with an AIC value of 38. Although this model could describe the 
variables in the model, this method might degrade the precision of the estimates of 
predictor variables in the model. 
This study has been an exploratory one. But, future studies can benefit from 
employing a larger sample population, a better strategy to deal with the missing 
values, a literature review and an expert advice in reducing the number of predictor 
variables, and by comparing with the alternative mathematical models such as Trees 
and neural networks at the same time (2, 6, 9, and 10).  
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Supplementary material  
 
Supplementary Table 1. Demographic and clinical characteristics of adrenal tumour (AT) 
patients 
 
  ACA (n=102)  ACC (n=45) 
     
     Median age (range) at time of urine 
collection (yr)  60 (19-84)  55(20-80) 
Sex (male, female)  39, 63  24, 21 
Tumour load at the time of collection  AT (n=102)  AT, no metastasis (n=9) 
    AT+metastasis (n=26) 
    
ACC metastasis after removal of 
primary tumour (n=10) 
Maximum diameter of AT at the time 
of urine collection  (median and 
range)  
26 (9-78) mm  90 (14-230)mm 
Surgical removal of AT  24/102 (24%)  30/45 (67%) 
Median Weiss score a  1 (0-2) (n= 15)  6 (3-9) (n=21) 
Duration of follow-up (median and 
range)  
52 (26-201) months 
since diagnosis (n=102)  
14 (1–187) months from diagnosis 
to death due to metastatic ACC in 
deceased patients (n=35)                           
45 (30–100) months since 
diagnosis in alive patients (n=10) 
 
a The Weiss system scores the presence or absence of nine histopathological features 
(Weiss score range 0–9); scores under 3 are indicative of a benign adrenal tumour, scores 
of 3 are borderline, and scores of 4 and above are indicative of malignancy (14). 
b Seven of the 10 surviving patients suffer from metastatic disease. The three remaining 
patients have not shown evidence of recurrence yet (all three initially presented with early-
stage disease [ENS@T II (13); primary tumour diameters 80, 89, and 160 mm; histology 
indicative of ACC with Weiss scores of 5, 7, and 4, respectively; current survival times 45, 
51, and 42 months, respectively]. 
** Taken from Wiebke et al. 2011(Reference 17). 
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Supplementary Table2.  Description of the steroid and steroid metabolites used in the study 
No.     Abbreviation Common  name Chemical name Metabolite of 
     
Androgen metabolites   
1 An  Androsterone  5α-androstan-3α-ol-17-one 
Androstenedione,testosterone, 
5α-dihydro testosterone 
2 Etio  Etiocholanolone  5β-androstan-3α-ol-17-one Androstenedione,testosterone 
 
Androgen precursor metabolites   
3 DHEA  Dehydroepi-androsterone 
5-androsten-3β-ol-17-
one 
DHEA + DHEA sulphate 
(DHEAS) 
4 16α-OHDHEA 16α-hydroxy-DHEA 5-androstene-3β,16α-diol-17-one DHEA + DHEAS 
5 5-PT  Pregnenetriol  5-pregnene-3β,17, 20α-triol  17-hydroxy pregnenolone 
6 5-PD  Pregnenediol  
5-pregnene-3β, 20α-
dioland 5, 17, (20)-
pregnadien-3β-ol 
pregnenolone 
Mineralocorticoid metabolites   
7 THA  Tetrahydro-11-dehydro corticosterone 
5β-pregnane-3α, 21-
diol,11, 20-dione 
corticosterone, 11-dehydro 
corticosterone 
8 5α-THA  5α-tetrahydro-11-dehydro corticosterone 
5α-pregnane-3α, 21-
diol-11,20-dione 
corticosterone, 11-dehydro 
corticosterone 
9 THB  Tetrahydro corticosterone 
5β-pregnane-3α, 
11β,21-triol-20-one corticosterone 
10 5α-THB  5α-tetrahydro corticosterone 
5α-pregnane-3α, 
11β,21-triol-20-one corticosterone 
11 3α5β-THALDO Tetrahydro aldosterone 
5β-pregnane-3α, 
11β,21-triol-20-one-
18-al 
aldosterone 
 
Mineralocorticoid precursor metabolites   
12 THDOC  Tetrahydro-11-deoxy corticosterone 
5β-pregnane-3α, 21-
diol-20-one 11-deoxy corticosterone 
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13 5α-THDOC  5α-tetrahydro-11-deoxy corticosterone 
5α-pregnane-3α, 21-
diol-20-one 11-deoxy corticosterone 
 
Glucocorticoid precursor metabolites   
14 PD  Pregnanediol  5β-pregnane-3α, 20adiol progesterone 
15 3α5α-17HP  3α, 5α-17-hydroxypregnanolone 
5α-pregnane-3α, 17α-
diol-20-one 17-hydroxy progesterone 
16 17HP  17-hydroxy pregnanolone 
5β-pregnane-3α, 
17α,-diol-20-one 17-hydroxy progesterone 
17 PT Pregnanetriol  5β-pregnane-3α, 17α,20α-triol 17-hydroxy progesterone 
18 PTONE  Pregnanetriolone 5β-pregnane-3α, 17,20α-triol-11-one 21-deoxycortisol 
19 THS  Tetrahydro-11-deoxycortisol 
5β-pregnane-3α, 17, 
21-triol-20-one 11-deoxycortisol 
 
Glucocorticoid metabolites   
20 F  Cortisol  4-pregnene-11β, 17, 21-triol-3, 20-dione cortisol 
21 6β-OH-F  6β-hydroxy-cortisol  
4-pregnene-6β, 11β, 
17,21-tetrol-3, 20-
dione 
cortisol 
22 THF  Tetrahydrocortisol  
5β-pregnane-3α, 
11β,17, 21-tetrol-20-
one 
cortisol 
23 5α-THF  5α-tetrahydrocortisol  
5α-pregnane-3α, 
11β,17, 21-tetrol-20-
one 
cortisol 
24 α-cortol  α-cortol  5β-pregnan-3α, 11β, 17,20α, 21-pentol cortisol 
25 β-cortol  β-cortol  5β-pregnan-3α, 11β, 17,20β, 21-pentol cortisol 
26 11β-OH-An  11β-hydroxy androsterone 
5α-androstane-3α, 
11β-diol-17-one cortisol (+androgens) 
27 11β-OH-Et  11β-hydroxy etiocholanolone 
5β-androstane-3α, 
11β-diol-17-one cortisol (+androgens) 
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28 E Cortisone  4-pregnene-17α, 21-diol-3, 11, 20-trione cortisone 
29 THE  Tetrahydro cortisone  5β-pregnene-3α, 17, 21-triol-11, 20-dione cortisone 
30 α-cortolone  α-cortolone  
5β-pregnane-3α, 
17,20α, 21-tetrol-11-
one 
cortisone 
31 β-cortolone  β-cortolone  
5β-pregnane-3α, 
17,20β, 21-tetrol-11-
one 
cortisone 
32 11-oxo-Et  11-oxo etiocholanolone 5β-androstan-3α-ol-11,17-dione cortisone (+androgens) 
** Taken from Wiebke et al. 2011(Reference 17). 
 
 
Supplementary Table3. Scripts used in model selection methods 
 
######   Stepwise regression 
> fit <- 
glm(cancer~P1+P2+P3+P4+P5+P6+P7+P8+P9+P11+P13+P15+P18+P19+P22+P24+P25+P26+P27
+P28+P29+P30+P31+P32+s10+s12+s14+s16+s17+s20+s21+s23,data=AT) 
 
> step <- stepAIC(fit, direction="both") 
 
Start:  AIC=60.3 
 
cancer ~ P1 + P2 + P3 + P4 + P5 + P6 + P7 + P8 + P9 + P11 + P13 +  
    P15 + P18 + P19 + P22 + P24 + P25 + P26 + P27 + P28 + P29 +  
    P30 + P31 + P32 + s10 + s12 + s14 + s16 + s17 + s20 + s21 +  
    s23 
 
 
#####  Stepwise backward elimination 
 
> fit <-
glm(cancer~P1+P2+P3+P4+P5+P6+P7+P8+P9+P11+P13+P15+P18+P19+P22+P24+P25+P26+P27
+P28+P29+P30+P31+P32+s10+s12+s14+s16+s17+s20+s21+s23,data=AT) 
 
> step <- stepAIC(fit, direction="backward") 
 
Start:  AIC=60.3 
 
cancer ~ P1 + P2 + P3 + P4 + P5 + P6 + P7 + P8 + P9 + P11 + P13 +  
    P15 + P18 + P19 + P22 + P24 + P25 + P26 + P27 + P28 + P29 +  
    P30 + P31 + P32 + s10 + s12 + s14 + s16 + s17 + s20 + s21 + s23 
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##### Script used to generate all subset combinations in the blue bear 
 
####data 
data<-(read.csv(file.choose(), header = T, sep = ",")) 
 
####Number of predictors 
preds<-32 
 
####Number chosen 
choose<-4 
 
library(gtools) 
 
####Number of combinations 
#library(combinat) 
#library(R.basic) 
#n_choose<-nChooseK(preds,choose) 
n_choose<-choose(preds,choose) 
 
####Time count 
 
time.start<-Sys.time() 
 
####Combinations 
 
pred_combs<-combinations(n=preds,r=choose) 
 
####Fitting models 
 
glm_output<-rep(0, n_choose) 
for (i in 1:n_choose) 
{ 
glm_m_output<-glm(data$cancer~data[, pred_combs[i,1]]+data[, pred_combs[i,2]]+data[, 
pred_combs[i,3]]+data[, pred_combs[i,4]], family="binomial") 
glm_output[i]<-glm_m_output$deviance 
} 
 
####deviance output and ordering 
 
deviance_mod<-cbind(pred_combs, glm_output) 
deviance_mod[order(deviance_mod[,5]),]  
deviance_mod<-as.data.frame(deviance_mod) 
 
time.end<-Sys.time() 
 
print(difftime(time.end, time.start)) 
 
write.table(deviance_mod, file="c://Prj2//Models_deviance//AT_chgv_logdeviance_mod3.csv", 
sep=",", row.names=FALSE, quote = FALSE) 
 
 
 
